Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models

Some antibacterial therapies entail sequential treatments with different antibiotics, but whether this approach is optimal for anti‐cancer tyrosine kinase inhibitors (TKIs) remains open. EGFR mutations identify lung cancer patients who can derive benefit from TKIs, but most patients develop resistan...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:EMBO Mol Med
Autores principales: Marrocco, Ilaria, Romaniello, Donatella, Vaknin, Itay, Drago‐Garcia, Diana, Oren, Roni, Uribe, Mary Luz, Belugali Nataraj, Nishanth, Ghosh, Soma, Eilam, Raya, Salame, Tomer‐Meir, Lindzen, Moshit, Yarden, Yosef
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8033519/
https://ncbi.nlm.nih.gov/pubmed/33660397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.202013144
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares